

Ecuador

Population 2016

16 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.4 (0.31–0.49)	2.4 (1.9–3)
Mortality (HIV+TB only)	0.34 (0.22–0.49)	2.1 (1.3–3)
Incidence (includes HIV+TB)	8.2 (5.3–12)	50 (33–72)
Incidence (HIV+TB only)	1.1 (0.69–1.5)	6.5 (4.2–9.2)
Incidence (MDR/RR-TB)**	0.71 (0.43–1)	4.4 (2.6–6.1)

Estimated TB incidence by age and sex (thousands)*, 2016

	0-14 years	> 14 years	Total
Females	0.47 (0.29–0.66)	2.6 (1.6–3.6)	3.1 (1.9–4.3)
Males	0.49 (0.3–0.69)	4.7 (2.9–6.5)	5.2 (3.2–7.2)
Total	0.97 (0.59–1.3)	7.3 (4.4–10)	8.2 (5.3–12)

TB case notifications, 2016

Total cases notified	5 374
Total new and relapse	5 284
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	89%
- % pulmonary	82%
- % bacteriologically confirmed among pulmonary	91%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2016	64% (45–99)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.09 (0.06–0.14)

TB/HIV care in new and relapse TB patients, 2016

	Number	(%)
Patients with known HIV-status who are HIV-positive	636	13%
- on antiretroviral therapy	583	92%

Drug-resistant TB care, 2016	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			370 (290–450)
Estimated % of TB cases with MDR/RR-TB	7.3% (5.4–9.2)	28% (25–31)	
% notified tested for rifampicin resistance			948
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 160, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 155, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2015	77%	5 097
Previously treated cases, excluding relapse, registered in 2015	51%	118
HIV-positive TB cases registered in 2015		
MDR/RR-TB cases started on second-line treatment in 2014	50%	120
XDR-TB cases started on second-line treatment in 2014		0

TB preventive treatment, 2016

% of HIV-positive people (newly enrolled in care) on preventive treatment	6%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	100% (100–100)

TB financing, 2017

National TB budget (US\$ millions)	1.7
Funding source: 100% domestic, international, 0% unfunded	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016




Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



— Unfunded
— Funded internationally
— Funded domestically